Adjunctive Aripiprazole in the Treatment of Risperidone-Induced Hyperprolactinemia

Summary

Hyperprolactinemia is a frequent consequence of treatment with typical antipsychotic agents and atypical antipsychotics such as risperidone. Recent studies have suggested that aripiprazole, a partial dopamine agonist, reduces the prolactin response to antipsychotics. Thus, we conducted this study to evaluate the dose effects of adjunctive treatment with aripiprazole on hyperprolactinemia in stable schizophrenic patients maintained with risperidone.

Timeline

Start

2013-02

Primary completion

2014-01

Completion

2014-02

Drugs

Indications